The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Specific Activity: 0.11 pmol/min/μg.
Assay conditions: 50 mM HEPES, pH 7.2, 50 mM NaCl, 10 mM EDTA, 0.1% Chaps, 5% glycerol, 10 mM DTT, and 10 μM Caspase 9 substrate. Incubate for 30 minutes at room temperature. Fluorescence intensity is measured at exc380/em505 nm.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped on Dry Ice. Store at -80°C. Avoid freeze / thaw cycle.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Apoptosis related cysteine peptidase
Apoptotic protease Mch-6
Apoptotic protease-activating factor 3
Caspase 9 apoptosis related cysteine peptidase
Caspase 9 Dominant Negative
Caspase-9 subunit p10
ICE like apoptotic protease 6
ICE-like apoptotic protease 6
protein phosphatase 1, regulatory subunit 56
Involved in the activation cascade of caspases responsible for apoptosis execution. Binding of caspase-9 to Apaf-1 leads to activation of the protease which then cleaves and activates caspase-3. Proteolytically cleaves poly(ADP-ribose) polymerase (PARP). Isoform 2 lacks activity is an dominant-negative inhibitor of caspase-9.
Ubiquitous, with highest expression in the heart, moderate expression in liver, skeletal muscle, and pancreas. Low levels in all other tissues. Within the heart, specifically expressed in myocytes.
Belongs to the peptidase C14A family. Contains 1 CARD domain.
Expressed at low levels in fetal heart, at moderate levels in neonate heart, and at high levels in adult heart.
Cleavages at Asp-315 by granzyme B and at Asp-330 by caspase-3 generate the two active subunits. Caspase-8 and -10 can also be involved in these processing events.